Oral GLP-1 drugs engage brain reward circuit in mice
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- University of Virginia researchers found that oral GLP-1 drugs orforglipron and danuglipron cut pleasure-driven (hedonic) eating in mice by engaging the central amygdala, a reward circuit deep in the brain.
- The newly mapped central amygdala pathway is separate from the hypothalamus and hindbrain systems already linked to injectable GLP-1 drugs such as semaglutide.
- Central amygdala activation reduced dopamine release in the brain's reward system during hedonic feeding, according to the study published in Nature (DOI: 10.1038/s41586-026-10444-4).
- Researchers used gene-editing techniques to modify mouse GLP-1 receptors so they resembled human receptors, enabling the small-molecule drugs to engage the pathway.
- Ali Güler, Ph.D., a UVA biology professor and co-corresponding author, said the drugs "dial back eating for pleasure by engaging a brain reward circuit."
- Follow-up studies will test whether oral GLP-1 drugs can reduce cravings for substances beyond food, with NIH's National Institute on Drug Abuse flagging potential implications for substance use disorder treatment.
- Orforglipron is FDA-approved; danuglipron remains experimental, and both small-molecule GLP-1s can be taken as pills and may cost less to manufacture than injectable peptide drugs such as Ozempic, Wegovy, and Rybelsus.
Why it matters: For NIH's addiction researchers, the more significant implication is that the same central amygdala pathway implicated in food cravings also drives drug and alcohol cravings — a therapeutic route into substance use disorder that the source notes will be tested in follow-up studies. With orforglipron already FDA-approved, this line of inquiry has a near-term clinical entry point distinct from the appetite-suppression story driving GLP-1 demand today.
